Shares of Cytos Biotechnology Ltd. plunged 32.8 percent on the Swiss stock exchange after the biotech said its vaccine candidate to treat hypertension, CYT006-AngQb, failed in a Phase IIa study to reduce patients' ambulatory blood pressures. (BioWorld Today)

Shares of United Therapeutics Corp. fell 10 percent Monday after the Silver Spring, Md.-based firm said it expected a delay in the approval of Tyvaso (treprostinil), an inhaled version of the company's approved pulmonary arterial hypertension (PAH) drug Remodulin, an injectable drug. (BioWorld Today)

WASHINGTON - While the ban now has been lifted on federal funding for human embryonic stem cell (hESC) research, several questions remain, including what constitutes responsible and scientifically worthy stem cell research, which has been left to the National Institutes of Health (NIH) to decide. (BioWorld Today)